Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT07541456
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Dr. Zarmina Younes
- Registry
-
NCT07541456
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT07541456. Randomized; single masking; primary purpose treatment. Start 2025-06-09 (actual); primary completion 2025-11-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
- Acronym
- EMPA-BP
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Hypertension
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Dr. Zarmina Younes
Record details
- Record id
cardio:ct-nct07541456- Content hash
f28e3f7aafb7f188936f745e051037b3c158ce75e553ea01f42b52e4b191361b